Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
This study will determine the Maximal Tolerated Dose if any and the recommended dose for
phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after
allogenic stem cell transplantation. All patients will receive one single intravenous
administration of one of the four doses of monalizumab.